AR126673A1 - Nuevas sales farmacéuticas y formas polimórficas de un inhibidor de erbb y btk - Google Patents

Nuevas sales farmacéuticas y formas polimórficas de un inhibidor de erbb y btk

Info

Publication number
AR126673A1
AR126673A1 ARP220102058A ARP220102058A AR126673A1 AR 126673 A1 AR126673 A1 AR 126673A1 AR P220102058 A ARP220102058 A AR P220102058A AR P220102058 A ARP220102058 A AR P220102058A AR 126673 A1 AR126673 A1 AR 126673A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical salts
polymorphic forms
erbb
new pharmaceutical
btk inhibitor
Prior art date
Application number
ARP220102058A
Other languages
English (en)
Spanish (es)
Inventor
Jun Zheng
- Jiang Jianan Cheng
Qinghai Guo
Shih Chang
- Zeng Qingbei Ying
Honchung Tsui
Zhenfan Yang
Xiaolin Zhang
Original Assignee
Dizal Jiangsu Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dizal Jiangsu Pharmaceutical Co Ltd filed Critical Dizal Jiangsu Pharmaceutical Co Ltd
Publication of AR126673A1 publication Critical patent/AR126673A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13Dicarboxylic acids
    • C07C57/145Maleic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13Dicarboxylic acids
    • C07C57/15Fumaric acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/185Saturated compounds having only one carboxyl group and containing keto groups
    • C07C59/225Saturated compounds having only one carboxyl group and containing keto groups containing —CHO groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP220102058A 2021-08-02 2022-08-02 Nuevas sales farmacéuticas y formas polimórficas de un inhibidor de erbb y btk AR126673A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2021110048 2021-08-02

Publications (1)

Publication Number Publication Date
AR126673A1 true AR126673A1 (es) 2023-11-01

Family

ID=85154265

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220102058A AR126673A1 (es) 2021-08-02 2022-08-02 Nuevas sales farmacéuticas y formas polimórficas de un inhibidor de erbb y btk

Country Status (11)

Country Link
US (1) US20250197377A1 (https=)
EP (1) EP4380924A4 (https=)
JP (1) JP2024529533A (https=)
KR (1) KR20240042640A (https=)
CN (1) CN117794902A (https=)
AR (1) AR126673A1 (https=)
AU (1) AU2022324410A1 (https=)
CA (1) CA3224748A1 (https=)
MX (1) MX2024001367A (https=)
TW (1) TW202321223A (https=)
WO (1) WO2023011358A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4731307A1 (en) 2023-06-23 2026-04-29 Assia Chemical Industries Ltd. Solid state forms of sunvozertinib

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014022790B1 (pt) * 2012-03-15 2022-04-19 Celgene Car Llc Sais de um inibidor de quinase de receptor de fator do crescimento epidermal, composição farmacêutica e usos do mesmo
CN105384694B (zh) * 2014-08-22 2020-09-04 四川海思科制药有限公司 一种取代的氨基嘧啶衍生物及其制备方法和药物用途
CN106905245B (zh) * 2015-12-23 2021-06-25 正大天晴药业集团股份有限公司 2,4-二取代的嘧啶类化合物
CN106083736A (zh) * 2016-06-21 2016-11-09 郑州泰基鸿诺医药股份有限公司 一种嘧啶类化合物、egfr抑制剂及其应用
TWI798334B (zh) * 2018-01-31 2023-04-11 大陸商迪哲(江蘇)醫藥股份有限公司 Erbb/btk抑制劑
WO2019177375A1 (ko) * 2018-03-13 2019-09-19 포로노이바이오 주식회사 2, 4, 5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
WO2023011358A1 (en) 2023-02-09
US20250197377A1 (en) 2025-06-19
CN117794902A (zh) 2024-03-29
KR20240042640A (ko) 2024-04-02
EP4380924A4 (en) 2025-10-01
MX2024001367A (es) 2024-02-27
JP2024529533A (ja) 2024-08-06
CA3224748A1 (en) 2023-02-09
TW202321223A (zh) 2023-06-01
EP4380924A1 (en) 2024-06-12
AU2022324410A1 (en) 2024-01-18

Similar Documents

Publication Publication Date Title
CO2022015638A2 (es) Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso
CY1124359T1 (el) Ενωσεις και συνθεσεις για ρυθμιση δραστικοτητων κινασης μεταλλακτικου egfr
CL2024002623A1 (es) Formas solidas, sales y procesos de preparacion de un inhibidor de cdk2.
MX2022001158A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
MX2020007947A (es) Inhibidores de erbb/btk.
CY1123661T1 (el) Κρυσταλλικη μορφη ενος αναστολεα της mdm2
CO2026004964A2 (es) Moduladores de kras
PE20191755A1 (es) Derivados de pirazol como inhibidores de malt 1
CR20190124A (es) Inhibidores de ssao de aminopirimidina
MX2022001562A (es) Formas solidas de un inhibidor de la cinasa 1 del progenitor hematopoyetico (hpk1).
CL2021001537A1 (es) Formas cristalinas y formas de sal de un inhibidor de cinasa
DOP2025000244A (es) Compuestos y métodos para el tratamiento de infecciones virales
MX2020011845A (es) Proceso para preparar acido 2-[[5-(3-clorofenil)-3-hidroxipiridina -2-carbonil]amino]acetico.
MX2025001016A (es) Derivados de piperidinilpiridinilcarbonitrilo como inhibidores de glutaminil-peptido ciclotransferasa y proteina tipo glutaminil-peptido ciclotransferasa
PY2219816A (es) Moduladores de sting (estimulador de genes de interferón)
MX2021015056A (es) Compuesto de pirrolopirimidina y uso del mismo.
CO2022006087A2 (es) Métodos para el tratamiento de la trombocitopenia inmunitaria mediante la administración de (r)-2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidino-1-carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enonitrilo
DOP2024000085A (es) Compuestos dirigidos a pmp22 para el tratamiento de la enfermedad de charcot-marie-tooth
CO2024009144A2 (es) Inhibidores de cinasa met
UY38233A (es) Agentes inhibidores para la tirosina cinasa de bruton
AR126673A1 (es) Nuevas sales farmacéuticas y formas polimórficas de un inhibidor de erbb y btk
CO2021005141A2 (es) Formas cristalinas sólidas de n-(1-((2-(dimetilamino)etil)amino)-2-metil-1-oxopropano-2-il)-4-(4-(2-metil-5-((2s,3r,4r,5s,6r)-3,4,5-trihidroxi-6-(metiltio)tetrahidro-2h-pirano-2-il)bencil)fenil)butanamida y métodos para su síntesis
PY1886949A (es) Inhibidor del receptor del factor de crecimiento epidérmico
EA201992744A1 (ru) Фармацевтические композиции n-(2-(2-(диметиламино)этокси)-4-метокси-5-((4-(1-метил-1h-индол-3-ил)пиримидин-2-ил)амино)фенил)акриламида и его солей
MX2026001029A (es) Derivados de piperidinilpiridinilcarbonitrilo como inhibidores de la glutamil-peptido ciclotransferasa y proteina similar a glutaminil-peptido ciclotransferasa